Rapid reduction of hepatitis C virus‐Core protein in the peripheral blood improve the immunological response in chronic hepatitis C patients
- 26 September 2011
- journal article
- Published by Wiley in Hepatology Research
- Vol. 41 (12) , 1153-1168
Abstract
Aim: The extracellular hepatitis C virus (HCV)‐antigen, including HCV‐Core protein, can suppress immune cells. Recently, the efficacy of double filtration plasmapheresis (DFPP) for chronic hepatitis C (CHC) was reported. However, the mechanism of efficacy of DFPP might not be only the reduction of HCV but also the effect of immune cells via direct and/or indirect mechanisms. The aim of this study is to analyze the virological and immunological parameters of difficult‐to‐treat HCV patients treated with DFPP combined with Peg‐interferon and RBV (DFPP/Peg‐IFN/RBV) therapy.Methods: Twelve CHC patients were enrolled and treated with DFPP/Peg‐IFN/RBV therapy. The immunological, virological and genetic parameters were studied.Results: All patients (4/4) treated with the major IL28B allele (T/T) could achieve complete early virological response (EVR). The amounts of HCV‐Core antigen in the peripheral blood of EVR patients treated with DFPP/Peg‐IFN/RBV rapidly declined in comparison to those of late virological response (LVR) patients treated with DFPP/Peg‐IFN/RBV and EVR patients treated with Peg‐IFN and RBV (Peg‐IFN/RBV). The amount of IFN‐γ produced from peripheral blood gradually increased. On the other hand, the amount of IL10 gradually decreased in the EVR patients. The frequencies of HCV‐Core binding on CD3+ T cells rapidly declined in EVR patients treated with DFPP/Peg‐IFN/RBV therapy. Moreover, the distributions of activated CD4+and CD8+ T cells and CD16‐CD56 high natural killer cells were significantly changed between before and after DFPP.Conclusions: The rapid reduction of HCV‐Core antigens and changes in the distribution of lymphoid cells could contribute to the favorable immunological response during DFPP/Peg‐IFN/RBV therapy.Keywords
This publication has 37 references indexed in Scilit:
- Therapeutic efficacy of double filtration plasmapheresis in patients with anti-aquaporin-4 antibody-positive multiple sclerosisJournal of Clinical Neuroscience, 2011
- Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis CHepatology Research, 2010
- Changes in the Lymphocyte Subset After Double-Filtration PlasmapheresisAmerican Journal of Clinical Pathology, 2007
- Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral loadHepatology Research, 2007
- Hemolysis in Double-Filtration PlasmapheresisAmerican Journal of Clinical Pathology, 2007
- Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary studyHepatology Research, 2006
- Efficacy of double-filtration plasmapheretic cross-circulation with a high-permeability membrane using canine harvested liver in porcine fulminant hepatic failure modelTransplantation Proceedings, 2004
- A Case Report of the Efficacy of Apheresis for Refractory Autoimmune Thrombocytopenia in a Patient with Systemic Lupus Erythematosus Associated Hemolytic AnemiaTherapeutic Apheresis and Dialysis, 2004
- Viral hepatitis CThe Lancet, 2003
- Double Filtration Plasmapheresis Enhances Neutrophil Chemotactic Responses in Hyperimmunoglobulin E SyndromeArtificial Organs, 1995